The safety of CoronaVac, the COVID-19 vaccine developed by China-based Sinovac BioTech, showed “remarkable” results across all age groups, including the elderly, according to the head of the vaccine development expert panel of DOST. | @CMRamosINQ
Anvisa, Brazil’s health care surveillance agency, restarted phase III trials for Coronavac, the COVID-19 vaccine candidate developed by China-based Sinovac Biotech, after a suspension of just two days.
Anvisa, Brazil’s health care surveillance agency, has halted the final-stage trials for Beijing, China-based Sinovac Biotech's COVID-19 vaccine candidate Coronavac after a serious adverse event occurred on Oct. 29
The government is set to increase Bio Farma’s production capacity as soon as a third clinical trial of China-based biopharmaceutical company Sinovac Biotech’s COVID-19 vaccine is finished and successful. #jakpost